Table of Contents Author Guidelines Submit a Manuscript
Journal of Pharmaceutics
Volume 2013, Article ID 265741, 7 pages
http://dx.doi.org/10.1155/2013/265741
Research Article

Preparation, Characterization and Evaluation of Quetiapine Fumarate Solid Lipid Nanoparticles to Improve the Oral Bioavailability

Department of Pharmaceutics, University College of Pharmaceutical Sciences, Kakatiya University, Warangal, Andhra Pradesh 506009, India

Received 4 February 2013; Revised 22 March 2013; Accepted 8 April 2013

Academic Editor: Kanchan Kohli

Copyright © 2013 Arjun Narala and Kishan Veerabrahma. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. C. Sweetman, Martindale, the Complete Drug Reference, Pharmaceutical Press, London, UK, 35th edition, 2007.
  2. C. J. H. Porter and W. N. Charman, “Intestinal lymphatic drug transport: an update,” Advanced Drug Delivery Reviews, vol. 50, no. 1-2, pp. 61–80, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. C. M. O'Driscoll, “Lipid-based formulations for intestinal lymphatic delivery,” European Journal of Pharmaceutical Sciences, vol. 15, no. 5, pp. 405–415, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. W. N. Charman and C. J. H. Porter, “Lipophilic prodrugs designed for intestinal lymphatic transport,” Advanced Drug Delivery Reviews, vol. 19, no. 2, pp. 149–169, 1996. View at Publisher · View at Google Scholar · View at Scopus
  5. W. Mehnert and K. Mäder, “Solid lipid nanoparticles production, characterization and applications,” Advanced Drug Delivery Reviews, vol. 47, no. 2-3, pp. 165–196, 2001. View at Publisher · View at Google Scholar
  6. R. H. Müller, W. Mehnert, J. S. Lucks et al., “Solid lipid nanoparticles (SLN)—an alternative colloidal carrier system for controlled drug delivery,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 41, no. 1, pp. 62–69, 1995. View at Google Scholar · View at Scopus
  7. R. H. Müller, K. Mäder, and S. Gohla, “Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 50, no. 1, pp. 161–177, 2000. View at Publisher · View at Google Scholar
  8. E. B. Souto, A. J. Almeida, and R. H. Müller, “Lipid nanoparticles (SLN, NLC) for cutaneous drug delivery: structure, protection and skin effects,” Journal of Biomedical Nanotechnology, vol. 3, no. 4, pp. 317–331, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. E. B. Souto and R. H. Müller, “Lipid nanoparticles (solid lipid nanoparticles and nanostructured lipid carriers) for cosmetic, dermal and transdermal applications,” in Nanoparticulate Drug Delivery Systems: Recent Trends and Emerging Technologies, D. Thassu, M. Deleers, and Y. Pathak, Eds., pp. 213–233, CRC Press, Boca Raton, Fla, USA, 2007. View at Google Scholar
  10. R. H. Müller, W. Mehnert, and E. B. Souto, “Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for dermal delivery,” in Percutaneous Absorption: Drugs, Cosmetics, Mechanisms, Methods (Drugs and the Pharmaceutical Sciences), R. L. Bronaugh and H. I. Maibach, Eds., pp. 719–738, Marcel Dekker, New York, NY, USA, 2005. View at Google Scholar
  11. A. Zur Mühlen, C. Schwarz, and W. Mehnert, “Solid lipid nanoparticles (SLN) for controlled drug delivery—drug release and release mechanism,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 45, no. 2, pp. 149–155, 1998. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Hu, X. Tang, and F. Cui, “Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs,” Journal of Pharmacy and Pharmacology, vol. 56, no. 12, pp. 1527–1535, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Hu, Q. Xing, J. Meng, and C. Shang, “Preparation and enhanced oral bioavailability of cryptotanshinone-loaded solid lipid nanoparticles,” AAPS PharmSciTech, vol. 11, no. 2, pp. 582–587, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Manjunath and V. Venkateswarlu, “Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration,” Journal of Controlled Release, vol. 107, no. 2, pp. 215–228, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Basavaiah, N. Rajendraprasad, P. J. Ramesh, and K. B. Vinay, “Sensitive ultraviolet spectrophotometric determination of quetiapine fumarate in pharmaceuticals,” Thai Journal of Pharmaceutical Sciences, vol. 34, no. 4, pp. 146–154, 2010. View at Google Scholar · View at Scopus
  16. F. Belal, A. Elbrashy, M. Eid, and J. J. Nasr, “Stability-indicating HPLC method for the determination of quetiapine: application to tablets and human plasma,” Journal of Liquid Chromatography and Related Technologies, vol. 31, no. 9, pp. 1283–1298, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Westesen, H. Bunjes, and M. H. J. Koch, “Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential,” Journal of Controlled Release, vol. 48, no. 2-3, pp. 223–236, 1997. View at Publisher · View at Google Scholar · View at Scopus